Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005627 · ClinicalTrials.gov registry record · Phase 1
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005627 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute.
The verdict
NCT00005627, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of estramustine, docetaxel, and carboplatin in treating patients who have prostate cancer that has not responded to hormonal therapy.
Interventions
- DRUG carboplatin
- DRUG docetaxel
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005627
The ClinicalTrials.gov registry entry for NCT00005627 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00005627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005627 about?
NCT00005627 is a clinical study titled "Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of estramustine, docetaxel, and carboplatin in treating patients who have...
What is the current status of trial NCT00005627?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-03. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00005627?
The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00005627?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.